DRUG
Bright Minds Biosciences IncKey Statistics
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc. (DRUG) is a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge therapies aimed at addressing central nervous system disorders, particularly in mental health and pain management. Leveraging its proprietary drug development platform, the company is advancing a robust pipeline of candidates that prioritize both efficacy and safety, amidst the increasing acceptance of psychedelic treatments. With a seasoned management team and a strong intellectual property portfolio, Bright Minds is strategically positioned to capture the growing demand for innovative mental health solutions, making it an attractive prospect for institutional investors seeking exposure to the evolving pharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -27.00% |
| Return on Assets | -15.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.38 |
| Price-to-Book | 13.04 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.79M |
| Float | $6.73M |
| % Insiders | 11.55% |
| % Institutions | 66.65% |
Historical Volatility
Volatility is currently contracting